Sacituzumab tirumotecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Triple Negative Breast Cancers
Conditions
Metastatic Triple Negative Breast Cancers
Trial Timeline
May 1, 2026 → May 1, 2029
NCT ID
NCT07458113About Sacituzumab tirumotecan
Sacituzumab tirumotecan is a phase 2 stage product being developed by Merck for Metastatic Triple Negative Breast Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07458113. Target conditions include Metastatic Triple Negative Breast Cancers.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Triple Negative Breast Cancers were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07438626 | Phase 2 | Recruiting |
| NCT07458113 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Triple Negative Breast Cancers